

Note

Simple preparations of alkyl and cycloalkyl α -glycosides of maltose, cellobiose, and lactose

Shinkiti Koto,* Motoko Hirooka, Takako Tashiro, Motokazu Sakashita, Masaharu Hatachi, Takayuki Kono, Miho Shimizu, Nahoko Yoshida, Sayaka Kurasawa, Natsuko Sakuma, Sunao Sawazaki, Akihiro Takeuchi, Naomi Shoya and Emi Nakamura

School of Pharmaceutical Sciences, Kitasato University, Shirokane, Minato-ku, Tokyo 108-8641, Japan

Received 5 May 2004; accepted 10 July 2004

This paper is dedicated to Dr. Yukio Ito

Abstract—Alkyl, cycloalkyl, allyl, 4-pentenyl, and benzyl α -glycosides of maltose, cellobiose, and lactose were prepared (17–77% yield; $\alpha/\beta = 70/30$ –96/4) via a direct reaction of the free disaccharides with a binary AcBr–AcOH mixture, followed by glycosidation with alcohol using FeCl_3 in MeNO_2 or CH_2Cl_2 , Zemplén deacetylation, and resolution of the anomeric mixture of glycosides by chromatography. Using MeCN as solvent for the glycosidation step, the corresponding β -biosides were also prepared (16–61% yield; $\alpha/\beta = 25/75$ –5/95).

© 2004 Elsevier Ltd. All rights reserved.

Keywords: α -Glycosidation; Iron(III) chloride; Glycosyl bromide; Disaccharide

Methyl, allyl, 4-pentenyl, and benzyl glycosides of such disaccharides as maltose (**1**), cellobiose (**2**), and lactose (**3**), are of diverse use as starting materials for various syntheses. Longer-chain alkyl biosides are widely used as nonionic surfactants¹ and are known to form liquid crystalline phases.² They are used as sugar acceptors for enzymatic glycosylation³ and as the lipophile-carrying head-moiety of artificial bioactive sugar clusters.⁴ Several biosides are probe-guests combining to receptor proteins⁵ and artificial receptors.^{6,7} Some long-chain alkyl maltosides enhance the nasal insulin absorption⁸ and the bioavailability of calcitonin.⁹

We present here convenient preparations of alkyl, cycloalkyl, allyl, 4-pentenyl, and benzyl α -glycosides of the common disaccharides, **1**, **2**, and **3**, directly from the respective free bioses, as shown in Figure 1. The procedure consists of (*i*) direct reaction of the bioses with a binary AcBr–AcOH system for 0.5 h, (*ii*) condensation

of the alcohol with the crude biosyl bromides in the presence of FeCl_3 (1–2 mol amount to the starting bioses) in MeNO_2 or CH_2Cl_2 for 1 h, (*iii*) deacetylation with methanolic NaOMe, and (*iv*) chromatographic resolution of the anomeric mixture of glycosides formed. When MeCN was used as the solvent in the glycosidation step for 1 h, as shown in Figure 2, the corresponding β -biosides were obtained.

The Fischer method has been used to prepare alkyl α -glycosides directly from glycoses, but its application to a disaccharide (biose) such as **1** is difficult,¹⁰ because of concurrent alcoholysis of the interglycosidic linkage.^{11–13} For example,¹³ the reaction of **1** with MeOH containing HCl (1%) at 20–25 °C for 4 days affords the corresponding disaccharide glycosides (biosides) in ~35% yield ($\alpha/\beta = \sim 50/50$). The direct glycosidation of **3** with neat 4-penten-1-ol by refluxing at 110 °C for 9 h with 10-camphorsulfonic acid¹⁴ was reported to give an anomeric mixture of the corresponding biosides, but their yields were not given. At present, alkyl α -biosides are best prepared indirectly; thus, the *in situ* anomerizing

* Corresponding author. E-mail: kotos@pharm.kitasato-u.ac.jp




Figure 1. Preparation of α -biosides: (a) AcBr/AcOH, room temperature (rt, ca. 25 °C), 0.5 h; (b) ROH+FeCl₃/MeNO₂ or CH₂Cl₂, rt, 1 h; (c) NaOMe/MeOH, rt, overnight; (d) AcBr/AcOH, 60 °C, 0.5 h.

glycosylation starting from the respective biose octaacetates is the most useful for obtaining alkyl α -biosides.¹⁵ However, the α -biosylation in the presence of SnCl₄ in CH₂Cl₂^{15–19} takes more than 4 h. Other methods, starting from 1-thio sugar derivatives,^{20,21} 1-O-(2,4,6-trimethylbenzoyl)sugars,²² 1-OH sugar derivatives,²³ and β -glycosides,²⁴ as well as enzymic methods,²⁵ require preparation of the particular donors. In contrast, alkyl β -biosides are readily prepared by the standard Koenigs–Knorr method.¹ Such β -biosides are also prepared by short reactions (2 h) using octaacetates and alcohol in the presence of SnCl₄^{15,17} or BF₃·Et₂O¹⁹ in CH₂Cl₂.

Direct reaction of the free disaccharides, **1** and **3** with AcBr^{26,27} is an old reaction, but is not frequently used, probably because of the difficultly controllable violent evolution of HBr.²⁸ Some years ago, we reported that direct preparation of the glycosyl bromides from free disaccharides **1** and **3** could be carried out at room temperature using a binary AcBr–AcOH mixture.^{29,30} However, this reaction with **2**, which is sparingly soluble

in the system, took over 5 h at room temperature. In this study, we found that this went to completion within 0.5 h at 60 °C. It was also found that reactions of **1** and **3** finished within 0.5 h at room temperature (\sim 25 °C). This binary AcBr–AcOH system is more efficient than the ternary Ac₂O–HBr–AcOH system for the direct acetobromination of free biooses; the latter takes more than 2 h for completion.^{31,32}

As the condensation reagent for the subsequent glycosidation using biosyl bromides, we used FeCl₃, since it was used as an α -glycosidation reagent for the condensation between biose octaacetates and alcohols in CHCl₃ at the reflux temperature,³³ but not for the Koenigs–Knorr reaction using the glycosyl bromides, which are expected to be more reactive than the glycosyl acetates. This reagent catalyzes the anomeralization of methyl hepta- O -acetyl- β -cellobioside,³⁴ the α -glycosidation of fully acetylated sugars,³⁵ the Ferrier reaction,³⁶ the Fischer reaction,³⁷ the formation of 1,6-anhydro sugars,³⁸ and the synthesis of β -glucosaminides.³⁹ we thus considered that FeCl₃ would be a good substitute for the standard




Figure 2. Preparation of β -biosides: (a) AcBr/AcOH , room temperature (rt, ca. 25°C), 0.5 h; (b) $\text{ROH}+\text{FeCl}_3/\text{MeCN}$, rt, 1 h; (c) NaOMe/MeOH , rt, overnight; (d) AcBr/AcOH , 60°C , 0.5 h.

reagents of the Koenigs-Knorr method. As shown in Table 1, the reactive biosyl bromides were converted within 1 h at room temperature in MeNO_2 or CH_2Cl_2 containing 1.0–1.5 mol of FeCl_3 relative to the starting bioses. For lower alcohols, MeNO_2 as solvent gave α -biosides with acceptable yields and α -selectivity. For higher ones, such as 1-hexadecanol and cyclopentadecanol, CH_2Cl_2 , in which they dissolve well, gave better results. The condensation with allyl alcohol in MeNO_2 containing only 1.0 mol amount of FeCl_3 to the starting sugars proceeded smoothly to give **4B**, **5B**, and **6B** in ~70% yield, whereas, in CH_2Cl_2 with a 1.5 mol amount of FeCl_3 , the yields were slightly low (<50%). Longer reaction time (3 h) in MeNO_2 slightly diminished the yield of biosides (~60%); but the selectivities were raised ($\alpha/\beta = \sim 95/5$), whereas shorter ones (0.5 h) in MeNO_2 gave similar yields (65–70%) but with lower selectivities ($\alpha/\beta = \sim 80/20$). The reactions with other metal salts such as CoBr_2 ⁴⁰ and ZnCl_2 ⁴¹ for 3 h resulted similar yields, but with lower selectivities ($\alpha/\beta = 60/40$ – $40/60$). In the case of benzyl alcohol, the yields of **4D**, **5D**,

and **6D** were low (~20%). When CH_2Cl_2 was used as the solvent, yields were improved (>50%), but the α -selectivities were low ($\alpha/\beta = \sim 60/40$). For the *n*-octyl α -biosides, **4E**, **5E**, and **6E**, the yields of the biosides using PhCF_3 ⁴² as solvent were comparable to those using MeNO_2 but the selectivities were very low ($\alpha/\beta = \sim 50/50$).

When the glycosidation was conducted in MeCN at room temperature for 1 h, as shown in Figure 2, the corresponding β -biosides were formed selectively ($\alpha/\beta = 25/75$ – $5/95$), in spite of a depression of the yields (Table 1). It seems that MeCN weakens the promoting effects of FeCl_3 , both for condensation and anomeration. In most cases, the amount of FeCl_3 could be increased to 2.0 mol to the starting bioses without significantly by raising the content of the α anomers. However, especially in synthesis of the lactosides of cycloalkanols, the anomeric ratios of the products were sensitive to the reaction time; thus extension of the reaction time to only 1.5 h raised the content of the α anomers. The β -biosides were thus obtained selectively in ~40% yield

Table 1. Results of preparations of disaccharides

Alcohol	FeCl ₃ /mol amount	Solvent	Yield/% (α/β)		
			Maltosides	Cellobiosides	Lactosides
Methanol	1.5	N	60 (95/5)	56 (87/13)	52 (89/11)
Methanol	2.0	A	26 (11/89)	33 (5/95)	27 (9/92)
Allylalcohol	1.0	N	71 (87/13)	77 (89/11)	65 (90/10)
Allylalcohol	2.0	A	52 (14/86)	61 (17/83)	58 (20/80)
4-Penten-1-ol	1.5	N	26 (70/30)	28 (73/27)	30 (75/25)
4-Penten-1-ol	1.5	A	39 (13/87)	43 (17/83)	45 (16/84)
Benzylalcohol	1.5	N	22 (86/14)	17 (94/6)	19 (92/8)
Benzylalcohol	2.0	A	34 (9/91)	58 (7/93)	57 (7/93)
1-Octanol	1.5	N	65 (93/7)	65 (96/4)	67 (92/8)
1-Octanol	2.0	A	39 (9/91)	30 (8/92)	34 (20/80)
1-Dodecanol	1.5	N	69 (91/9)	57 (91/9)	60 (98/11)
1-Dodecanol	2.0	A	34 (18/82)	40 (18/82)	31 (19/81)
1-Hexadecanol	1.5	D	56 (95/5)	62 (85/15)	50 (95/5)
1-Hexadecanol	2.0	A	49 (5/95)	21 (5/95)	27 (20/80)
Cyclopentanol	1.5	N	63 (87/13) ^a	71 (88/12)	52 (87/13)
Cyclopentanol	2.0	A	20 (17/83)	32 (17/83)	40 (23/77) ^b
Cyclohexanol	1.5	N	69 (84/16)	66 (86/14)	73 (87/13)
Cyclohexanol	2.0	A	25 (22/78)	30 (10/90)	34 (23/77) ^b
Cyclooctanol	1.0	N	21 (86/14)	22 (94/6)	26 (86/14)
Cyclooctanol	2.0	A	16 (17/83)	19 (20/80)	22 (25/75)
Cyclododecanol	1.5	N	50 (88/12)	56 (91/9)	51 (95/5)
Cyclododecanol	2.0	A	26 (5/95)	26 (17/83)	43 (22/78) ^b
Cyclopentadecanol	1.5	D	74 (87/13)	65 (92/8)	55 (91/9)
Cyclopentadecanol	2.0	A	32 (17/83)	24 (6/94)	25 (5/95) ^b

^a FeCl₃ (1.0 mol amount) was used.^b FeCl₃ (1.5 mol amount) was used.

at best, except for the allyl β -biosides, **7B**, **8B**, and **9B**, (50–60% yield; $\alpha/\beta = \sim 20/80$).

1. Experimental

1.1. General methods

The solvent systems for column chromatography on silica gel (Kanto Kagaku, No 37047; gradient elusion) and thin-layer chromatography (TLC) (Merck, DC-Plastikfolien Kieselgel 60 F 254, Art. 5735) were CHCl₃–MeOH (CM) and PhMe–butanone (TK), and that for column chromatography on Dowex 1 \times 2 was a pyridine–MeOH (PM) system.

Solvents were evaporated from solutions obtained at 35–45 °C under diminished pressure, unless otherwise noted. The melting points were determined on a Yanaco Micro Melting Point Apparatus (Yanagimoto). Optical rotations were measured on a Jasco DIP-180 digital polarimeter at room temperature. The ¹H and ¹³C NMR spectra were recorded with a Varian XL-400 spectrometer, along with measurements of H,H-COSY, C,H-COSY, and DEPT spectra. Spectral assignments were made by auxiliary measurements of HOHAHA, HMQC, HMBC, GHMQC, and differential NOE spectra. HRMS were recorded with a Jeol JMS-AX505HA spectrometer or a Jeol JMS-700 spectrometer. The ¹H NMR data of the biosides pre-

pared are given in Tables 2 and 3 and their ¹³C NMR data are in Tables 4 and 5.[†]

1.2. Synthesis of biosides

A mixture of **1** or **3** (monohydrate, 1.0 g, 2.8 mmol), AcBr (3.6 mL, 44.4 mmol), and AcOH (19 mL) was stirred at room temperature (~25 °C) for 0.5 h to give a homogeneous solution. The mixture was concentrated below 25 torr at 30 °C, co-evaporated three times with dry PhMe (5 mL), and evacuated below 25 torr at 50 °C for 15 min to give a foam [HRMS (FAB) Found: from **1**, *m/z* 721.0964 and from **3**, *m/z* 721.0990. Calcd for C₂₆H₃₅BrNaO₁₁ [M+Na]⁺: 721.0955]. To the crude bromide, the solvent (10 mL), alcohol (5.6 mmol), and FeCl₃ were added with vigorous stirring at room temperature for 1 h. To the mixture, aq KBr (10%, 25 mL) and then PhMe (60 mL) were added under stirring. The organic phase was washed with aq KBr (10%, 25 mL, twice), aq NaHCO₃ (5%, 25 mL), and H₂O (25 mL, twice). The organic layer was evaporated to dryness. The resultant mixture was dissolved in MeOH (30 mL) containing methanolic NaOMe (7%, 2 mL) and the solution stirred at room temperature overnight. After the addition of AcOH (0.2 mL), the mixture was

[†]Note added in proof: the supplementary NMR data are available at <http://kitasato-u.ac.jp/medicinal>.

Table 2. ^1H NMR data of selected α -biosides determined at 400 MHz (M = CD₃OD, W = D₂O)

Compounds (Solv.)	4A (W)	4E (W)	4F (M)	4L (M)	5A (W)	5E (W)	5F (M)	5L (M)	6A (W)	6E (W)	6F (M)	6L (M)
H-1 ^I	4.78	4.86	4.77	4.89	4.78	4.85	4.77	4.89	4.77	4.86	4.78	4.88
J _{1,2}	4.0	4.0	4.0	4.0	4.0	4.0	4.0	4.0	4.0	3.5	4.0	4.0
H-2 ^I	3.56	3.56	3.45	3.43	3.58	3.57	3.45	3.44	3.57	3.58	3.46	3.44
J _{2,3}	10.0	9.0	10.0	10.0	10.0	9.5	9.5	10.0	9.5	9.0	9.5	9.5
H-3 ^I	3.89	3.92	3.88	3.86	3.76	3.80	3.76	3.75	3.75	3.82	3.77	3.75
J _{3,4}	9.0	9.0	9.0	9.5	9.0	8.5	9.0	9.0	10.0	9.0	8.5	10.0
H-4 ^I	3.62	3.66	3.51	3.53	3.61	3.64	3.54	3.36	3.61	3.67	3.54	3.55
J _{4,5}	9.0	9.5	10.0	9.5	10.0	9.5	9.5	9.5	10.0	9.0	10.0	10.0
H-5 ^I	3.73	3.64	3.62	3.70	3.78	3.70	3.68	3.77	3.73	3.72	3.69	3.79
J _{5,6a}	4.5	6.0	4.5	2.0	4.0	5.5	2.0	2.0	5.0	5.5	2.0	2.0
J _{5,6b}	2.0	2.0	2.0	6.0	2.0	3.0	4.5	4.0	2.0	3.5	4.0	4.0
H-6a ^I	3.77	3.76	3.81	3.77	3.82	3.79	3.80	3.76	3.81	3.78	3.81	3.80
H-6b ^I	3.85	3.83	3.83	3.86	3.89	3.91	3.88	3.91	3.89	3.91	3.86	3.89
J _{6a,b}	12.0	13.0	12.0	12.0	12.0	11.0	12.0	12.0	12.0	10.0	12.0	12.0
H-1 ^{II}	5.36	5.28	5.15	5.15	4.48	4.50	4.40	4.41	4.40	4.42	4.35	4.36
J _{1,2}	4.0	4.0	4.0	4.0	8.0	8.0	8.0	8.0	8.0	8.0	7.5	7.5
H-2 ^{II}	3.53	3.56	3.45	3.45	3.29	3.32	3.24	3.24	3.50	3.55	3.55	3.55
J _{2,3}	10.0	9.5	10.0	9.5	10.0	9.0	8.5	9.0	10.0	10.0	9.5	9.5
H-3 ^{II}	3.65	3.66	3.63	3.61	3.48	3.49	3.38	3.88	3.62	3.65	3.48	3.49
J _{3,4}	9.0	9.5	9.0	9.0	9.0	9.5	9.0	9.0	3.5	3.5	3.0	3.0
H-4 ^{II}	3.38	3.41	3.27	3.26	3.39	3.38	3.32	3.33	3.88	3.90	3.82	3.82
J _{4,5}	9.5	9.5	10.0	9.5	9.0	9.0	10.0	9.5	1.0	1.0	1.0	1.0
H-5 ^{II}	3.68	3.66	3.69	3.67	3.46	3.46	3.35	3.37	3.66	3.70	3.59	3.59
J _{5,6a}	5.5	5.0	6.0	5.5	6.0	5.5	5.0	5.5	4.0	3.5	4.5	4.0
J _{5,6b}	2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0	7.0	8.0	7.5	6.0
H-6a ^{II}	3.73	3.76	3.68	3.65	3.70	3.70	3.67	3.67	3.70	3.72	3.70	3.70
H-6b ^{II}	3.82	3.79	3.83	3.84	3.90	3.89	3.88	3.88	3.77	3.78	3.79	3.79
J _{6a,b}	12.0	12.0	11.5	12.0	11.5	11.0	11.5	11.5	13.0	12.0	11.5	12.0

Aglycon; **4A**: 3.38 (s, Me); **4E**: 0.85 (t, J = 6.5 Hz, Me); **4F**: 0.90 (t, J = 7.0 Hz, Me); **5A**: 3.40 (s, Me); **5E**: 0.84 (t, J = 6.5 Hz, Me); **5F**: 0.90 (t, J = 7.0 Hz, Me); **6A**: 3.53 (s, Me); **6E**: 0.85 (t, J = 6.0 Hz, Me); **6F**: 0.90 (t, J = 6.0 Hz, Me).

evaporated to dryness and chromatographed with the CM system (100:1 → 1:10) to give first the β anomer and then α anomer. Accompanying bioses as impurities, if any, were separated by chromatography on a Dowex 1 × 2 (OH form, 100–200 mesh) with the PM system (10:1 → 1:10).⁴³ Further purification was by recrystallization from the specified solvents or by repeated chromatography. The α/β values in Tables 1–3 are based on the weights of the isolated anomers and those of fractions containing both anomers whose anomeric ratios were determined from their ^1H NMR spectra. The R_f values of the β anomers of each anomeric pair of biosides were greater than those of the corresponding α anomers by TLC using the CM system.

The acetobromination of **2** was performed under more-vigorous conditions as follows: a mixture of **2** (1.0 g, 2.9 mmol), AcBr (19 mL, 0.23 mmol), and AcOH (19 mL) was stirred at 60 °C for 0.5 h (compound **2** from Sigma needed longer warming, for 1 h) to afford a homogeneous solution, which was evaporated to dryness as before to give a crystalline solid [HRMS (FAB) Found: m/z 721.0963. Calcd for C₂₆H₃₅BrNaO₁₁ [M+Na]⁺: 721.0955].

The physical constants (melting points and specific rotations in the specified solvents in the literature for)

of **4A**,^{10,11,13,20,21} **7A**,^{11–13} **5A**,^{12,21} **8A**,¹² **6A**,²¹ **9A**,⁴⁴ **9B**,⁴⁵ **7D**,⁴⁶ **8D**,⁴⁷ **9D**,⁴⁸ **7E**,⁴⁹ **8E**,^{50,51} **7F**,^{49,52–54} **8F**,^{50,53} **8G**,⁵⁰ **4I**,¹⁰ **8I**,⁵⁵ all showed correct m/z value by HRMS (FAB), agreement with the reported data within experimental error.

1.2.1. Allyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4B**).** Glass; $[\alpha]_D^{25} + 158$ (c 0.8, H₂O); HRMS (FAB) Calcd for C₁₅H₂₆NaO₁₁ [M+Na]⁺: 405.1373. Found: m/z 405.1381.

1.2.2. Allyl α -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (7B**).** Glass; $[\alpha]_D^{25} + 70$ (c 0.8, H₂O); HRMS (FAB) Calcd for C₁₅H₂₆NaO₁₁ [M+Na]⁺: 405.1373. Found: m/z 405.1384.

1.2.3. Allyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5B**).** Glass; $[\alpha]_D^{25} + 82$ (c 0.7, H₂O); HRMS (FAB) Calcd for C₁₅H₂₆NaO₁₁ [M+Na]⁺: 405.1373. Found: m/z 405.1371.

1.2.4. Allyl β -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (8B**).** Glass; $[\alpha]_D^{25} - 22$ (c 0.8, H₂O); HRMS (FAB) Calcd for C₁₅H₂₆NaO₁₁ [M+Na]⁺: 405.1373. Found: m/z 405.1376.

Table 3. ^1H NMR data of selected β -biosides determined at 400 MHz (M = CD₃OD, P = C₅H₅N with CD₃OD, W = D₂O)

Compounds (Solv.)	7A (W)	7E (W)	7F (M)	7L (M)	8A (W)	8E (W)	8F (P)	8L (P)	9A (W)	9E (M)	9F (P)	9L (P)
H-1 ^I	4.35	4.37	4.28	4.33	4.36	4.37	4.80	4.90	4.37	4.28	4.78	4.88
J _{1,2}	8.0	8.0	8.0	7.5	8.0	8.0	8.0	8.0	8.0	8.0	8.0	8.0
H-2 ^I	3.25	3.28	3.23	3.20	3.26	3.30	4.03	4.00	3.27	3.24	4.03	4.00
J _{2,3}	9.5	9.0	9.0	8.5	9.5	9.0	9.0	9.0	9.0	8.0	8.5	8.5
H-3 ^I	3.73	3.72	3.62	3.62	3.60	3.59	4.27	4.29	3.60	3.52	4.27	4.28
J _{3,4}	9.0	9.0	9.0	9.0	9.5	9.0	9.0	9.0	10.0	9.0	9.0	9.0
H-4 ^I	3.59	3.62	3.54	3.56	3.58	3.61	4.33	4.35	3.61	3.57	4.33	4.35
J _{4,5}	10.0	9.5	9.5	9.0	9.0	10.0	9.5	9.0	10.0	9.0	9.0	9.0
H-5 ^I	3.55	3.48	3.37	3.35	3.57	3.50	3.90	3.93	3.58	3.40	3.87	3.89
J _{5,6a}	4.5	4.5	4.5	3.5	4.5	5.0	2.5	2.5	4.0	5.0	3.0	3.0
J _{5,6b}	2.0	2.0	2.0	2.5	2.0	2.0	4.0	4.0	2.0	2.0	4.0	4.0
H-6a ^I	3.73	3.77	3.81	3.66	3.77	3.82	4.49	4.48	3.77	3.84	4.49	4.47
H-6b ^I	3.90	3.87	3.88	3.87	3.95	3.89	4.56	4.57	3.95	3.90	4.56	4.56
J _{6a,b}	12.0	12.0	12.0	11.0	12.5	12.0	12.0	12.0	12.0	12.5	12.0	12.0
H-1 ^{II}	5.36	5.34	5.17	5.16	4.46	4.50	5.19	5.20	4.41	4.47	5.14	5.15
J _{1,2}	4.0	4.0	4.0	4.0	8.0	8.0	8.0	8.5	8.0	7.5	8.0	8.0
H-2 ^{II}	3.54	3.55	3.45	3.45	3.27	3.30	4.09	4.08	3.50	3.56	4.54	4.52
J _{2,3} ^{II}	10.0	9.5	9.5	9.5	9.5	9.0	8.5	8.5	10.0	10.0	9.0	10.0
H-3 ^{II}	3.64	3.65	3.65	3.58	3.46	3.45	4.21	4.21	3.63	3.49	4.17	4.16
J _{3,4}	9.0	9.5	9.0	9.0	9.0	9.5	9.0	9.0	3.5	3.5	3.5	3.0
H-4 ^{II}	3.37	3.39	3.27	3.26	3.37	3.39	4.17	4.16	3.88	3.82	4.49	4.49
J _{4,5}	10.0	9.5	9.5	9.0	9.0	10.0	9.0	9.0	1.0	1.0	1.0	1.0
H-5 ^{II}	3.67	3.67	3.69	3.69	3.44	3.47	4.01	4.00	3.68	3.59	4.15	4.13
J _{5,6a}	5.0	5.0	6.5	4.0	5.5	5.5	6.0	6.0	4.0	4.0	5.0	4.5
J _{5,6b}	2.0	2.0	2.0	2.5	2.0	2.0	2.5	2.5	7.5	7.0	7.0	6.0
H-6a ^{II}	3.73	3.74	3.75	3.80	3.69	3.71	4.29	4.27	3.70	3.70	4.37	4.36
H-6b ^{II}	3.82	3.81	3.89	3.87	3.88	3.89	4.53	4.52	3.75	3.78	4.46	4.44
J _{6a,b}	12.0	12.5	11.0	12.0	12.5	12.5	12.0	11.5	12.0	11.0	11.0	11.0

Aglycon; **7A**: 3.53 (s, Me); **7E**: 0.84 (t, J = 7.0 Hz, Me); **7F**: 0.91 (t, J = 6.5 Hz, Me); **8A**: 3.53 (s, Me); **8E**: 0.84 (t, J = 6.5 Hz, Me); **8F**: 0.89 (t, J = 7.0 Hz, Me); **9A**: 3.53 (s, Me); **9E**: 0.89 (t, J = 6.5 Hz, Me); **9F**: 0.88 (t, J = 6.0 Hz, Me).

Table 4. ^{13}C NMR data of selected α -biosides determined at 100 MHz (M = CD₃OD, W = D₂O)

Compounds (Solv.)	4A (W)	4E (W)	4F (M)	4L (M)	5A (W)	5E (W)	5F (M)	5L (M)	6A (W)	6E (W)	6F (M)	6L (M)
C-1 ^I	101.7	101.1	100.0	98.4	101.7	100.9	99.9	98.9	101.7	101.0	98.7	198.4
C-2 ^I	73.7	73.8	73.2	73.0	73.7	73.8	73.3	73.9	73.58	73.8	72.1	73.4
C-3 ^I	76.2	76.2	74.9	74.7	74.7	74.5	73.5	73.7	74.4	74.5	72.3	73.2
C-4 ^I	79.5	80.7	81.8	81.6	81.3	81.2	81.0	81.5	81.1	80.8	79.8	80.9
C-5 ^I	72.7	73.1	72.3	72.3	72.9	73.1	72.1	72.7	72.9	73.2	70.9	72.2
C-6 ^I	63.20	63.0	62.1	61.8	62.6	62.6	61.8	62.2	62.6	62.6	60.7	61.8
C-1 ^{II}	102.3	103.2	102.9	102.8	105.2	105.2	104.6	105.0	105.6	105.6	103.9	105.1
C-2 ^{II}	74.4	74.6	74.3	74.1	75.8	75.8	74.9	75.4	73.63	73.6	71.4	72.6
C-3 ^{II}	75.5	75.8	75.1	74.9	78.2	78.4	77.9	78.3	75.2	75.4	73.6	74.8
C-4 ^{II}	72.0	71.7	71.5	71.4	72.1	72.2	71.4	71.8	71.2	71.3	69.1	70.3
C-5 ^{II}	75.3	75.5	74.7	74.6	78.8	78.7	78.1	78.6	78.0	78.0	76.0	77.0
C-6 ^{II}	63.15	63.1	62.7	62.6	63.3	63.4	62.4	62.9	63.7	63.8	61.3	62.5

Aglycon; **4A**: 57.7 (Me); **4E**: 16.5, 25.2, 28.5, 31.8 (2C), 31.9, 34.4, 71.1 (*n*-octyl); **4F**: 14.4, 23.7, 27.3, 30.5, 30.6 (2C), 30.7 (2C), 30.8 (2C), 33.1, 69.3 (*n*-dodecyl); **4L**: 24.0, 24.4, 27.5 (3C), 27.67, 27.74 (3C), 27.9, 28.2, 28.3, 32.5, 34.1, 78.1 (cyclopentadecyl); **5A**: 57.8 (Me); **5E**: 16.4, 25.1, 28.5, 31.8 (2C), 31.9, 34.4, 71.2 (*n*-octyl); **5F**: 14.4, 23.7, 27.3, 30.5, 30.6 (2C), 30.7 (2C), 30.75, 30.77, 33.1, 69.3 (*n*-dodecyl); **5L**: 24.7, 25.1, 28.2 (3C), 28.3, 28.4 (3C), 28.6, 28.9, 29.0, 33.2, 34.7, 78.8 (cyclopentadecyl); **6A**: 57.8 (Me); **6E**: 16.4, 25.2, 28.5, 31.8, 31.88, 31.93, 34.4, 71.2 (*n*-octyl); **6F**: 13.3, 22.5, 26.2, 29.3, 29.4(2C), 29.5, 29.56, 29.59(2C), 31.9, 68.2 (*n*-dodecyl); **6L**: 24.2, 24.6, 27.7 (3C), 27.8, 27.9 (3C), 28.1, 28.4, 28.5, 32.7, 34.2, 78.3 (cyclopentadecyl).

1.2.5. Allyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6B**).** Glass; $[\alpha]_D^{25} + 106$ (*c* 1.1, H₂O); HRMS (FAB) Calcd for C₁₅H₂₆NaO₁₁ [M+Na]⁺: 405.1373. Found: *m/z* 405.1366.

1.2.6. 4-Pentenyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4C**).** Glass; $[\alpha]_D^{25} + 146$ (*c* 0.8, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1681.

Table 5. ^{13}C NMR data of selected β -biosides determined at 100 MHz (M = CD₃OD, P = C₅H₅N with CD₃OD, W = D₂O)

Compounds (Solv.)	7A (W)	7B (W)	7C (M)	7D (M)	8E (W)	8F (W)	8G (P)	8H (P)	8I (W)	8J (M)	8K (P)	8L (P)
C-1 ^I	105.8	105.0	104.2	103.0	105.7	105.1	104.5	103.3	105.8	104.2	104.5	103.2
C-2 ^I	75.7	75.6	74.6	74.7	75.5	75.5	74.86	75.01	75.5	74.7	74.9	75.0
C-3 ^I	78.9	79.0	77.8	77.8	77.0	77.2	76.9	76.9	77.1	76.4	76.7	76.7
C-4 ^I	79.4	79.9	81.2	81.2	81.3	81.5	81.4	81.6	81.1	80.7	81.9	82.0
C-5 ^I	77.2	77.3	76.5	76.4	77.4	77.4	76.7	76.6	77.4	76.4	76.6	76.5
C-6 ^I	63.4	63.4	62.7	62.7	62.7	62.9	62.2	62.4	62.7	61.9	62.2	62.3
C-1 ^{II}	102.2	102.6	102.8	102.7	105.2	105.3	105.1	105.1	105.6	105.1	105.8	105.8
C-2 ^{II}	74.3	74.4	74.1	74.1	75.8	75.9	74.91	74.96	73.6	72.5	72.6	72.6
C-3 ^{II}	75.5	75.4	75.0	75.0	78.2	78.3	78.3	78.3	75.2	74.8	75.2	75.2
C-4 ^{II}	72.0	71.9	71.4	71.5	72.1	72.1	71.6	71.6	71.2	70.3	70.2	70.3
C-5 ^{II}	75.4	75.6	74.7	74.7	78.6	78.7	78.6	78.6	78.0	77.0	77.3	77.3
C-6 ^{II}	63.2	63.2	62.1	62.1	63.2	63.3	62.5	62.5	63.7	62.5	62.2	62.2

Aglycon; **7A**: 59.8 (Me); **7E**: 16.4, 25.1, 28.2, 31.7, 31.81, 31.84, 34.3, 73.1 (*n*-octyl); **7F**: 14.5, 23.8, 27.1, 30.5, 30.6, 30.76 (3C), 30.80 (2C), 33.1, 70.9 (*n*-dodecyl); **7L**: 24.0, 24.3, 27.7 (2C), 27.76, 27.82, 27.9 (2C), 27.97, 28.03, 28.48, 28.52, 32.9, 34.3, 79.8 (cyclopentadecyl); **8A**: 59.9 (Me); **8E**: 16.4, 25.2, 28.3, 31.9 (3C), 34.4, 73.2 (*n*-octyl); **8F**: 14.5, 23.1, 26.6, 29.8, 30.0, 30.10 (3C), 30.14, 30.5 32.3, 70.2 (*n*-dodecyl); **8L**: 23.3, 23.6, 27.0 (3C), 27.27 (4C), 27.33, 27.85, 27.92, 32.4, 34.0, 78.8 (cyclopentadecyl); **9A**: 59.9 (Me); **9E**: 14.4, 23.7, 27.1, 30.4, 30.5, 30.8, 33.0, 71.0 (*n*-octyl); **9F**: 14.4, 23.1, 26.6, 29.8, 30.0, 30.07 (3C), 30.10, 30.4, 32.3, 70.1; **9L**: 23.3, 23.6, 27.0 (3C), 27.2 (4C), 27.3, 27.8, 32.4, 33.9, 78.8 (cyclopentadecyl).

1.2.7. 4-Pentenyl α -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (7C). Glass; $[\alpha]_D^{25} + 59$ (*c* 1.5, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1691.

1.2.8. 4-Pentenyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5C). Glass; $[\alpha]_D^{25} + 72$ (*c* 1.0, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1675.

1.2.9. 4-Pentenyl β -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (8C). Glass; $[\alpha]_D^{25} - 16$ (*c* 1.0, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1697.

1.2.10. 4-Pentenyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6C). Glass; $[\alpha]_D^{25} + 89$ (*c* 1.1, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1664.

1.2.11. 4-Pentenyl β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9C). Glass; $[\alpha]_D^{26} + 2$ (*c* 0.5, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1703.

1.2.12. Benzyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4D). Glass; $[\alpha]_D^{25} + 162$ (*c* 0.4, H₂O); HRMS (FAB) Calcd for C₁₉H₂₈NaO₁₁ [M+Na]⁺: 455.1529. Found: *m/z* 455.1537.

1.2.13. Benzyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5D). Glass; $[\alpha]_D^{25} + 85$ (*c* 0.5, H₂O); HRMS (FAB) Calcd for C₁₉H₂₈NaO₁₁ [M+Na]⁺: 455.1529. Found: *m/z* 455.1553.

1.2.14. Benzyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6D). Glass; $[\alpha]_D^{24} + 118$ (*c* 0.7, H₂O);

HRMS (FAB) Calcd for C₁₉H₂₈NaO₁₁ [M+Na]⁺: 455.1529. Found: *m/z* 455.1552.

1.2.15. n-Octyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4E). Glass; $[\alpha]_D^{23} + 138$ (*c* 1.1, MeOH); HRMS (FAB) Calcd for C₂₀H₃₈NaO₁₁ [M+Na]⁺: 477.2312. Found: *m/z* 477.2324.

1.2.16. n-Octyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5E). Glass; $[\alpha]_D^{26} + 61$ (*c* 0.6, MeOH); HRMS (FAB) Calcd for C₂₀H₃₈NaO₁₁ [M+Na]⁺: 477.2312. Found: *m/z* 477.2352.

1.2.17. n-Octyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6E). Glass; $[\alpha]_D^{27} + 87$ (*c* 0.9, MeOH); HRMS (FAB) Calcd for C₂₀H₃₈NaO₁₁ [M+Na]⁺: 477.2312. Found: *m/z* 477.2310.

1.2.18. n-Octyl β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9E). Glass; $[\alpha]_D^{27} + 3$ (*c* 0.8, MeOH); HRMS (FAB) Calcd for C₂₀H₃₈NaO₁₁ [M+Na]⁺: 477.2312. Found: *m/z* 477.2340.

1.2.19. n-Dodecyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4F). Glass; $[\alpha]_D^{25} + 122$ (*c* 0.9, C₅H₅N); HRMS (FAB) Calcd for C₂₄H₄₆NaO₁₁ [M+Na]⁺: 533.2938. Found: *m/z* 533.2909.

1.2.20. n-Dodecyl β -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (5F). Crystals (from MeOH); mp 150–153 °C; $[\alpha]_D^{24} + 46$ (*c* 0.5, C₅H₅N); HRMS (FAB) Calcd for C₂₄H₄₆NaO₁₁ [M+Na]⁺: 533.2938. Found: *m/z* 533.2939. Anal. Calcd for C₂₄H₄₆O₁₁·H₂O: C, 54.53, H, 9.15. Found: C, 54.83, H, 8.86.

1.2.21. n-Dodecyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6F). Crystals (from MeOH); mp

160–162 °C; $[\alpha]_D^{24} + 64$ (*c* 0.7, C₅H₅N); HRMS (FAB) Calcd for C₂₄H₄₆NaO₁₁ [M+Na]⁺: 533.2938. Found: *m/z* 533.2924. Anal. Calcd for C₂₄H₄₆O₁₁·0.5H₂O: C, 55.48, H, 9.12. Found: C, 55.21, H, 8.98.

1.2.22. *n*-Dodecyl β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9F). Crystals (from MeOH); mp 106–111 °C; $[\alpha]_D^{25} + 8$ (*c* 0.6, C₅H₅N); HRMS (FAB) Calcd for C₂₄H₄₆NaO₁₁ [M+Na]⁺: 533.2938. Found: *m/z* 533.2937. Anal. Calcd for C₂₄H₄₆O₁₁·0.5H₂O: C, 55.48, H, 9.12. Found: C, 55.20, H, 8.84.

1.2.23. *n*-Hexadecyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4G). Crystallized spontaneously[‡]; mp 195–202 °C; $[\alpha]_D^{25} + 98$ (*c* 0.5, C₅H₅N); HRMS (FAB) Calcd for C₂₈H₅₄NaO₁₁ [M+Na]⁺: 589.3564. Found: *m/z* 589.3574.

1.2.24. *n*-Hexadecyl α -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (7G). Crystals (from MeOH); mp 111–116 °C; $[\alpha]_D^{24} + 45$ (*c* 0.5, C₅H₅N); HRMS (FAB) Calcd for C₂₈H₅₄NaO₁₁ [M+Na]⁺: 589.3564. Found: *m/z* 589.3533. Anal. Calcd for C₂₈H₅₄O₁₁: C, 59.34, H, 9.60. Found: C, 59.12, H, 9.58.

1.2.25. *n*-Hexadecyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5G). Crystals (from MeOH); mp 119–126 °C; $[\alpha]_D^{25} + 43$ (*c* 0.5, C₅H₅N); HRMS (FAB) Calcd for C₂₈H₅₄NaO₁₁ [M+Na]⁺: 589.3564. Found: *m/z* 589.3586. Anal. Calcd for C₂₈H₅₄O₁₁·0.5H₂O: C, 58.41, H, 9.63. Found: C, 58.53, H, 9.57.

1.2.26. *n*-Hexadecyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6G). Crystals (from MeOH), mp 172–176 °C; $[\alpha]_D^{23} + 58$ (*c* 0.9, pyridine); HRMS (FAB) Calcd for C₂₈H₅₄NaO₁₁ [M+Na]⁺: 589.3564. Found: *m/z* 589.3527. Anal. Calcd for C₂₈H₅₄O₁₁·H₂O: C, 57.51, H, 9.65. Found: C, 57.77, H, 9.36.

1.2.27. *n*-Hexadecyl β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9G). Crystals (from MeOH), mp 175–178 °C; $[\alpha]_D^{25} + 9$ (*c* 0.3, pyridine+Me₂SO (1:1)); HRMS (FAB) Calcd for C₂₈H₅₄NaO₁₁ [M+Na]⁺: 589.3564. Found: *m/z* 589.3565. Anal. Calcd for C₂₈H₅₄O₁₁·H₂O: C, 57.51, H, 9.65. Found: C, 57.57, H, 9.47.

1.2.28. Cyclopentyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4H). Glass; $[\alpha]_D^{25} + 156$ (*c* 0.8, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1680.

1.2.29. Cyclopentyl α -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (7H). Glass; $[\alpha]_D^{25} + 67$ (*c* 1.5, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1686.

1.2.30. Cyclopentyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5H). Glass; $[\alpha]_D^{25} + 75$ (*c* 1.0, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1680.

1.2.31. Cyclopentyl β -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (8H). Glass; $[\alpha]_D^{25} - 22$ (*c* 1.0, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1688.

1.2.32. Cyclopentyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6H). Glass; $[\alpha]_D^{25} + 106$ (*c* 1.1, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1689.

1.2.33. Cyclopentyl β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9H). Glass; $[\alpha]_D^{26} + 1$ (*c* 0.5, H₂O); HRMS (FAB) Calcd for C₁₇H₃₀NaO₁₁ [M+Na]⁺: 433.1686. Found: *m/z* 433.1672.

1.2.34. Cyclohexyl α -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (7I). Glass; $[\alpha]_D^{25} + 74$ (*c* 0.9, H₂O); HRMS (FAB) Calcd for C₁₈H₃₂NaO₁₁ [M+Na]⁺: 447.1842. Found: *m/z* 447.1853.

1.2.35. Cyclohexyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5I). Glass; $[\alpha]_D^{26} + 69$ (*c* 0.9, H₂O); HRMS (FAB) Calcd for C₁₈H₃₂NaO₁₁ [M+Na]⁺: 447.1842. Found: *m/z* 447.1824.

1.2.36. Cyclohexyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6I). Glass; $[\alpha]_D^{26} + 102$ (*c* 1.3, H₂O); HRMS (FAB) Calcd for C₁₈H₃₂NaO₁₁ [M+Na]⁺: 447.1842. Found: *m/z* 447.1846.

1.2.37. Cyclohexyl β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9I). Glass; $[\alpha]_D^{25} + 5$ (*c* 1.0, H₂O); HRMS (FAB) Calcd for C₁₈H₃₂NaO₁₁ [M+Na]⁺: 447.1842.

1.2.38. Cyclooctyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4J). Glass; $[\alpha]_D^{24} + 124$ (*c* 0.6, MeOH); HRMS (FAB) Calcd for C₂₀H₃₆NaO₁₁ [M+Na]⁺: 475.2155. Found: *m/z* 475.2179.

1.2.39. Cyclooctyl α -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (7J). Glass; $[\alpha]_D^{26} + 51$ (*c* 1.1, MeOH); HRMS (FAB) Calcd for C₂₀H₃₆NaO₁₁ [M+Na]⁺: 475.2155. Found: *m/z* 475.2163.

[‡]Glasses obtained crystallized spontaneously but, on the addition of a small amount of MeOH or EtOH, began to liquefy. The addition of EtOAc, Me₂CO, or Et₂O to them did not afford crystals.

1.2.40. Cyclooctyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5J). Glass; $[\alpha]_D^{26} + 55$ (*c* 0.7, MeOH); HRMS (FAB) Calcd for $C_{20}H_{36}NaO_{11}$ $[M+Na]^+$: 475.2155. Found: *m/z* 475.2176.

1.2.41. Cyclooctyl β -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (8J). Glass; $[\alpha]_D^{25} - 5$ (*c* 1.1, MeOH); HRMS (FAB) Calcd for $C_{20}H_{36}NaO_{11}$ $[M+Na]^+$: 475.2155. Found: *m/z* 475.2155.

1.2.42. Cyclooctyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6J). Crystallized spontaneously¹; mp 120–125 °C; $[\alpha]_D^{28} + 72$ (*c* 0.5, MeOH); HRMS (FAB) Calcd for $C_{20}H_{36}NaO_{11}$ $[M+Na]^+$: 475.2155. Found: *m/z* 475.2148.

1.2.43. Cyclooctyl β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9J). Glass; $[\alpha]_D^{25} + 7$ (*c* 0.9, MeOH); HRMS (FAB) Calcd for $C_{20}H_{36}NaO_{11}$ $[M+Na]^+$: 475.2155. Found: *m/z* 475.2141.

1.2.44. Cyclododecyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4K). Glass; $[\alpha]_D^{24} + 115$ (*c* 0.5, pyridine); $R_f = 0.46$ (CHCl₃–MeOH = 2:1); HRMS (FAB) Calcd for $C_{24}H_{44}NaO_{11}$ $[M+Na]^+$: 531.2781. Found: *m/z* 531.2771.

1.2.45. Cyclododecyl α -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (7K). Crystals (from MeOH); mp 195–197 °C; $[\alpha]_D^{25} + 48$ (*c* 0.9, pyridine); HRMS (FAB) Calcd for $C_{24}H_{44}NaO_{11}$ $[M+Na]^+$: 531.2781. Found: *m/z* 531.2784. Anal. Calcd for $C_{24}H_{44}O_{11}\cdot 0.5H_2O$: C, 55.69, H, 8.76. Found: C, 55.97, H, 8.53.

1.2.46. Cyclododecyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5K). Crystals (from MeOH), mp 206–207 °C; $[\alpha]_D^{23} + 38$ (*c* 1.2, pyridine); HRMS (FAB) Calcd for $C_{24}H_{44}NaO_{11}$ $[M+Na]^+$: 531.2781. Found: *m/z* 531.2801. Anal. Calcd for $C_{24}H_{44}O_{11}\cdot 0.5H_2O$: C, 55.69, H, 8.76. Found: C, 55.70, H, 8.64.

1.2.47. Cyclododecyl β -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (8K). Crystals (from MeOH), mp 231–238 °C; $[\alpha]_D^{23} - 12$ (*c* 1.0, pyridine); HRMS (FAB) Calcd for $C_{24}H_{44}NaO_{11}$ $[M+Na]^+$: 531.2781. Found: *m/z* 531.2787. Anal. Calcd for $C_{24}H_{44}O_{11}\cdot 0.5H_2O$: C, 55.69, H, 8.76. Found: C, 55.70, H, 8.64.

1.2.48. Cyclododecyl β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6K). Crystals (from MeOH), mp 207–209 °C; $[\alpha]_D^{25} + 56$ (*c* 0.6, pyridine); HRMS (FAB) Calcd for $C_{24}H_{44}NaO_{11}$ $[M+Na]^+$: 531.2781. Found: *m/z* 531.2751. Anal. Calcd for $C_{24}H_{44}O_{11}\cdot 0.5H_2O$: C, 55.69, H, 8.76. Found: C, 55.49, H, 8.53.

1.2.49. Cyclododecyl β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9K). Prisms (from MeOH), mp 212–213 °C; $[\alpha]_D^{25} + 5$ (*c* 0.6, pyridine); HRMS (FAB) Calcd for $C_{24}H_{44}NaO_{11}$ $[M+Na]^+$: 531.2781. Found: *m/z* 531.2788. Anal. Calcd for $C_{24}H_{44}O_{11}$: C, 56.68, H, 8.72. Found: C, 56.28, H, 8.78.

1.2.50. Cyclopentadecyl α -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (4L). Glass; $[\alpha]_D^{26} + 91$ (*c* 0.8, pyridine); HRMS (FAB) Calcd for $C_{27}H_{50}NaO_{11}$ $[M+Na]^+$: 573.3251. Found: *m/z* 573.3272.

1.2.51. Cyclopentadecyl α -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (7L). Glass; $[\alpha]_D^{23} + 41$ (*c* 1.1, pyridine); HRMS (FAB) Calcd for $C_{27}H_{50}NaO_{11}$ $[M+Na]^+$: 573.3251. Found: *m/z* 573.3268.

1.2.52. Cyclopentadecyl β -D-glucopyranosyl-(1 → 4)- α -D-glucopyranoside (5L). Glass; $[\alpha]_D^{27} + 44$ (*c* 0.9, pyridine); HRMS (FAB) Calcd for $C_{27}H_{50}NaO_{11}$ $[M+Na]^+$: 573.3251. Found: *m/z* 573.3224.

1.2.53. Cyclopentadecyl- β -D-glucopyranosyl-(1 → 4)- β -D-glucopyranoside (8L). Crystals (from MeOH), mp 198–206 °C; $[\alpha]_D^{24} - 12$ (*c* 0.8, pyridine); HRMS (FAB) Calcd for $C_{27}H_{50}NaO_{11}$ $[M+Na]^+$: 573.3251. Found: *m/z* 573.3258. Anal. Calcd for $C_{27}H_{50}O_{11}\cdot 0.5H_2O$: C, 57.02, H, 9.22. Found: C, 56.97, H, 9.06.

1.2.54. Cyclopentadecyl- β -D-galactopyranosyl-(1 → 4)- α -D-glucopyranoside (6L). Crystallized spontaneously[‡]; mp 121–123 °C; $[\alpha]_D^{25} + 53$ (*c* 0.8, pyridine); HRMS (FAB) Calcd for $C_{27}H_{50}NaO_{11}$ $[M+Na]^+$: 573.3251. Found: *m/z* 573.3250.

1.2.55. Cyclopentadecyl- β -D-galactopyranosyl-(1 → 4)- β -D-glucopyranoside (9L). Crystals (from MeOH); mp 154–158 °C; $[\alpha]_D^{25} + 5$ (*c* 0.7, pyridine); HRMS (FAB) Calcd for $C_{27}H_{50}NaO_{11}$ $[M+Na]^+$: 573.3251. Found: *m/z* 573.3245. Anal. Calcd for $C_{27}H_{50}O_{11}\cdot 0.5H_2O$: C, 57.94, H, 9.18. Found: C, 58.00, H, 9.08.

References

- VanAken, T.; Foxall-VanAken, S.; Castleman, S.; Ferguson-Miller, S. *Methods Enzymol.* **1986**, *125*, 27–35.
- Vill, V.; Hashim, R. *Curr. Opin. Coll. Interface Sci.* **2002**, *7*, 395–409.
- Izumi, M.; Shen, G.-J.; Wacowich-Sgarbi, S.; Nakatani, T.; Plettenburg, O.; Wong, C.-H. *J. Am. Chem. Soc.* **2001**, *123*, 10909–10918.
- Yi, Y.; Zhou, Z.; Ning, J.; Kong, F.; Li, J. *Synthesis* **2003**, *22*, 491–496.
- Meyar, B.; Peters, T. *Angew. Chem., Int. Ed.* **2003**, *42*, 864–890.
- Droz, A. S.; Neidlein, U.; Anderson, S.; Seiler, P.; Diederich, F. *Helv. Chim. Acta* **2001**, *84*, 2243–2289.

7. Lecollinet, G.; Dominey, A. P.; Velasco, T.; Davis, A. P. *Angew. Chem., Int. Ed.* **2002**, *41*, 4093–4096.
8. Pillion, D. J.; Ahsan, F.; Arnold, J. J.; Balusubramanian, B. M.; Piraner, O.; Meezan, E. *J. Pharm. Sci.* **2002**, *91*, 1456–1462.
9. Ahsan, F.; Arnold, J.; Meezan, E.; Pillion, D. *J. Pharm. Res.* **2001**, *18*, 1742–1746.
10. Matsubara, S. *Bull. Chem. Soc. Jpn.* **1961**, *34*, 718–722.
11. Zurabyan, S. E.; Bílik, V.; Bauer, S. *Chem. Zvesti* **1969**, *23*, 923–927.
12. Piekarska, B. *Roczn. Chem.* **1975**, *49*, 1919–1925.
13. Cheetham, N. W. H.; Sirimanne, P. *Carbohydr. Res.* **1981**, *96*, 126–128.
14. Grande, D.; Baskaran, S.; Chaikof, E. L. *Polym. Mater. Sci. Eng.* **2001**, *84*, 141–142.
15. Banoub, J.; Bundle, D. R. *Can. J. Chem.* **1987**, *57*, 2085–2090.
16. Mazur, A. W.; Hiler, G. D., Jr. *Carbohydr. Res.* **1987**, *168*, 146–150.
17. Vill, V.; Böcker, T.; Thiem, J.; Fischer, F. *Liq. Cryst.* **1989**, *6*, 349–356.
18. Böcker, T.; Thiem, J. *Tenside Surf. Det.* **1989**, *26*, 318–324.
19. VonMinden, H. M.; Brandenburg, K.; Saydel, U.; Koch, M. H. J.; GaramusV; Willumeit, R.; Vill, V. *Chem. Phys. Lipids* **2000**, *106*, 157–179.
20. Dick, W. E., Jr.; Weisleder, D.; Hodge, J. E. *Carbohydr. Res.* **1971**, *18*, 115–123.
21. Gi, G. T.; Ishihara, H.; Tejima, S. *Chem. Pharm. Bull.* **1978**, *26*, 1570–1575.
22. Helferich, B.; Piel, W. *Justus Liebigs Ann. Chem.* **1959**, *623*, 124–128.
23. Klots, W.; Schmidt, R. R. *J. Carbohydr. Chem.* **1994**, *13*, 1093–1101.
24. Inouye, Y.; Onodera, K.; Karasawa, I.; Nishisawa, Y. *Nippon Noge Kagaku Kaishi* **1952**, *26*, 631–634.
25. Totani, K.; Yasutake, N.; Ohi, H.; Murata, T.; Usui, T. *Arch. Biochem. Biophys.* **2001**, *385*, 70–77.
26. Ditmar, R. *Monatsh. Chem.* **1902**, *23*, 865–876.
27. Fischer, E.; Fischer, H. *Chem. Ber.* **1910**, *43*, 2521–2536.
28. Ito, Y.; Koto, S.; Umezawa, S. *Bull. Chem. Soc. Jpn.* **1962**, *35*, 1618–1622.
29. Koto, S.; Morishima, N.; Irisawa, T.; Hashimoto, Y.; Yamazaki, M.; Zen, S. *Nippon Kagaku Kaishi*, **1982**, 1651–1656.
30. Koto, S.; Morishima, N.; Shichi, S.; Haigoh, H.; Hirooka, M.; Okamoto, M.; Higuchi, T.; Shimizu, K.; Hashimoto, Y.; Iriawa, T.; Kawasaki, H.; Takahashi, Y.; Yamazaki, M.; Mori, Y.; Kudo, K.; Ikegaki, T.; Suzuki, S.; Zen, S. *Bull. Chem. Soc. Jpn.* **1992**, *65*, 3257–3274.
31. Kartha, C. P. R.; Jennings, H. J. *J. Carbohydr. Chem.* **1990**, *9*, 777–781.
32. Larsen, K.; Olsen, C. E.; Motawia, M. S. *Carbohydr. Res.* **2003**, *338*, 199–202.
33. Zemplén, G.; Csürös, Z. *Chem. Ber.* **1931**, *64*, 993–1000.
34. Ikemoto, N.; Kim, O. K.; Lo, L.-C.; Satyanarayana, V.; Chang, M.; Nakanishi, K. *Tetrahedron Lett.* **1992**, *33*, 4295–4298.
35. Chatterjee, S. K.; Nuhn, P. *Chem. Commun.* **1998**, 1729–1730.
36. Masson, C.; Soto, J.; Bessodes, M. *Synlett* **2000**, *22*, 1281–1282.
37. Ferrieres, V.; Bertho, J.-N.; Plusquellec, D. *Carbohydr. Res.* **1998**, *311*, 23–35.
38. Miranda, P. O.; Brouard, I.; Padrón, J. I.; Bermejo, J. *Tetrahedron Lett.* **2003**, *44*, 3931–3934.
39. Kiso, M.; Anderson, L. *Carbohydr. Res.* **1985**, *136*, 309–323.
40. Koto, S.; Morishima, N.; Zen, S. *Bull. Chem. Soc. Jpn.* **1982**, *55*, 1543–1547.
41. Watanabe, Y.; Nakamoto, C.; Yamamoto, T.; Ozaki, S. *Tetrahedron* **1994**, *50*, 6523–6536.
42. Yamada, H.; Hayashi, T. *Carbohydr. Res.* **2002**, *337*, 581–585.
43. Rosevear, P.; VanAken, T.; Baxter, J.; Ferguson-Miller, S. *Biochemistry* **1980**, *19*, 4108–4115.
44. Ali, M. A.; Hough, L.; Richardson, A. C. *Carbohydr. Res.* **1991**, *216*, 271–287.
45. Youssef, R. H.; Silwanis, B. A.; El-Sokkary, R. I.; Nematalla, A. S.; Nashed, M. A. *Carbohydr. Res.* **1993**, *240*, 287–293.
46. Fischer, H.; Kögl, F. *Justus Liebigs Ann. Chem.* **1924**, *436*, 219–228.
47. Edwards, R. G.; Hough, L.; Richardson, A. C. *Carbohydr. Res.* **1977**, *55*, 129–148.
48. Jung, K.-H.; Hoch, M.; Schmidt, R. R. *Liebigs Ann. Chem.* **1989**, *1099*–1106.
49. Boyd, B. J.; Drummond, C. J.; Krodkiewska, I.; Grieser, F. *Langmuir* **2000**, *16*, 7359–7367.
50. Hori, R. *Yakugaku Zasshi* **1958**, *78*, 999–1002.
51. Ma, Y.-D.; Takada, A.; Sugiura, M.; Fukuda, T.; Miyamoto, T.; Watanabe, J. *Bull. Soc. Chem. Jpn.* **1994**, *67*, 346–351.
52. DeGrip, W. J.; Bovee-Geurts, P. H. M. *Chem. Phys. Lipids* **1979**, *23*, 321–335.
53. Landauer, P.; Ruess, K.-P.; Liefländer, M. *Biochem. Biophys. Res. Commun.* **1982**, *106*, 848–855.
54. Koeltzow, D. E.; Urfer, A. D. *J. Am. Oil Chem. Soc.* **1984**, *61*, 1651–1655.
55. Brandon, R. E.; Schroeder, L. R.; Johnson, D. C. *ACS Symp. Ser.* **1975**, *22*, 125–146.